Mastery of innovative bioproduction techniques
The LFB group has mastered various bioproduction techniques, some of which are particularly innovative.
LFB produces recombinant proteins through cell culture at its Alès site in France (LFB BIOMANUFACTURING), which boasts specific know-how in the field of monoclonal antibodies. LFB BIOMANUFACTURING produces clinical batches of recombinant proteins and monoclonal antibodies.
The group’s American subsidiaries (rEVO BIOLOGICS Inc. and LFB USA) specialise in the development and manufacture of highly innovative recombinant medicines using a technology that involves the expression of the required protein through DNA recombination in mammalian milk. The protein is then isolated, purified and made safety compliant according to the highest pharmaceutical standards, based on LFB’s cutting edge expertise in these areas. These medicines are known as lactorecombinants.
LFB’s subsidiary CELLforCURE is a key industrial and pharmaceutical player in the emerging field of cell therapy. With a capacity of 5,000 batches per year, CELLforCURE’s industrial facility is the first modular entity of this size in Europe and is able to produce up to eight different cell therapy medicines simultaneously. CELLforCURE operates based on a combined model, as both a CMO (Contract Manufacturing Organisation) offering production services, and a pharmaceutical company that develops, manufactures and markets cell therapy medicinal products.